Covance Remains Upbeat on Future as Q4 Exceeds Expectations

By Zachary Brennan

- Last updated on GMT

Covance Remains Upbeat on Future as Q4 Exceeds Expectations
Covance management sounded relatively upbeat about its expectations for 2013 as late-stage clinical trials continue to grow and IT spending begins to taper off, company officials said on Friday.

Management has a high degree of confidence in its mid-teens growth target for 2013 as an unusually high 88% of this revenue is already booked​,” Jeffries analysts said in an investor note.

As fourth quarter revenue came in higher than expectations, the company and analysts seem to agree that revenue growth in 2013 will be in the mid to high single digits as the rapid growth in late-stage development is offset by underperformance in early-stage trials.  

Joseph Herring, chairman and CEO of Covance, said in the conference call that the company is either one of two or one of three CROs working with seven of the top 20 biggest pharmaceutical companies and “we're increasing literally with all of them... The large strategic deals that we've signed that are very visible took a little longer to get going because they had other agreements, but they're starting to ramp​.”

He added that research and development spending has grown more than expected and it’s likely that this trend will continue into 2013 as Covance’s clients “are becoming a bit more buoyant, especially since FDA approvals are at one of the highest levels in recent memory​.”

Covance is also expecting its investments in IT to pay off over the next few years. IT spending is expected to continue to grow by 17% in 2013, but it will slow considerably in 2014 to between two and three percent.

We are going to bring tools to clients they aren’t used to seeing: in terms of predicting and forecasting trials, estimating trial supplies, as well as metrics and dashboards to stay on top of their trial in real time​,” Herring said.

Clinical orders were also up by about 40% in fiscal year 2012, and Covance remains confident in its ability to deliver at least mid-teens revenue growth in FY2013.

In addition, hiring in late-stage development more than offset the company’s cutbacks in early stage employees.

Jeffries analysts noted that the current bookings could mean “continued growth, and margins appear sustainable barring cancellations or an uncharacteristic, aggressive strategic deal.”

Related news

Show more

Related products

VDS groß

Meet the challenges of complex injectables

Vetter Pharma International GmbH | 07-Nov-2017 | Technical / White Paper

In the time it takes from the exciting discovery phase to the rigorous demands of a commercial launch, unexpected scientific and technical challenges can...


Process Development for Lyophilized Products

Baxter BioPharma Solutions | 30-Oct-2017 | Application Note

Baxter approaches formulation and process development with the intention of identifying the failure points for the product. Knowing where the product fails...


Advancing therapeutics for myeloma

Recipharm AB | 04-Sep-2017 | Case Study

Multiple myeloma is the second most common blood cancer in the world and despite survival rates increasing over the last decade, there remains a requirement...

Related suppliers